Pacer Inc

COVID-19 DEVELOPMENT OF LUNGPACER-PPROTECT, A NEUROSTIMULATION DEVICE TO IMPROVE RESPIRATORY HEALTH AND OUTCOMES FOR MECHANICALLY VENTILATED PATIENTS

PARENT TRAINING & INFORMATION TECHNICAL ASSISTANCE CENTERS

PACER'S MINNESOTA STATEWIDE FAMILY ENGAGEMENT CENTER

PARENTAL INFORMATION AND RESOURCE CENTERS

PARENT TRAINING AND INFORMATION CENTER

PACER'S PARENTS TRAINING PARENTS PROJECT

MECHANISM TO PROMOTE SAFE AND EFFICIENT ORAL FEEDING IN PRETERM INFANTS - PROJECT SUMMARY/ABSTRACT THERE ARE 380,000 INFANTS BORN PRETERM EACH YEAR IN THE UNITED STATES ALONE. PRETERM INFANTS OFTEN NECESSITATE CARE IN THE NEONATAL INTENSIVE CARE UNIT. ONE OF THE FINAL MILESTONES TO BE ACHIEVED IN ORDER TO BE DISCHARGED FROM THE NEONATAL INTENSIVE CARE UNIT IS ORAL FEEDING. ORAL FEEDING CAN BE A CHALLENGE FOR INFANTS BORN PRETERM AS THEY DO NOT HAVE THE MATURITY THAT ALLOWS FOR COORDINATED SUCKING, SWALLOWING, AND BREATHING. MANY INFANTS WILL SUCK AND SWALLOW, AND THEIR FAILURE TO BREATHE WILL RESULT IN DANGEROUS PHYSIOLOGICAL FLUCTUATIONS. TO HELP WITH THIS, PACING TECHNIQUES CAN BE USED. CAUTIOUS CAREGIVERS CAN INTERMITTENTLY PULL THE BOTTLE NIPPLE OUT OF THE INFANT’S MOUTH TO ENCOURAGE BREATHING AND RECOVERY. THIS CAN BE DISRUPTIVE TO THE FEEDING PROCESS, CAN RESULT IN SIGNIFICANT ENERGY EXPENDITURE, AND CAN BE STRESSFUL FOR PARENTS. TO ADDRESS THIS PROBLEM, THE PREEMIE-PACER BOTTLE IS IN DEVELOPMENT. THE PREEMIE-PACER HAS AN INTERNAL MECHANISM THAT INTERRUPTS THE FLOW OF MILK TO THE NIPPLE INTERMITTENTLY TO ENABLE THE INFANT TO PAUSE AND BREATHE. THE LONG-TERM GOAL OF THIS PROJECT IS TO DEVELOP AN INNOVATIVE BOTTLE THAT WILL ADDRESS THE PROBLEMS THAT PRETERM INFANTS EXPERIENCE DURING EARLY ORAL FEEDING, ALLOWING EARLY FEEDS TO OCCUR SAFELY AND EFFICIENTLY. THE CURRENT PROJECT AIMS ARE TO 1) OPTIMIZE THE DESIGN OF THE PREEMIE-PACER BOTTLE WITH THE ADDITION OF AN ‘ASSESSMENT MODE’ AND INTERNAL MEMORY UNIT, EXTERNAL DISPLAY, AND RECHARGEABLE BASE FOLLOWED BY DOING LABORATORY TESTING, AND 2) IMPROVE USABILITY BY DEFINING PROGRAMMING FOR INDIVIDUALIZED USE OF THE PREEMIE-PACER. TO ACHIEVE THIS, DESIGN WORK WILL BE FOLLOWED BY LABORATORY TESTING OF THE DEVICE TO ENSURE ITS DURABILITY, REPEATABILITY AND RELIABILITY. THEN 100 PRETERM INFANTS BORN =32 WEEKS GESTATION WILL BE FED TWO TIMES EACH WEEK BY A NEONATAL THERAPIST WHO WILL CONTROL THE FLOW OF MILK USING A SENSOR ON THE BOTTLE, ACCORDING TO THE INFANT’S BEHAVIORAL SIGNS. DATA WILL BE DOWNLOADED AND POOLED AND ALGORITHMS FIT TO THE DATA TO ESTABLISH APPROPRIATE TIMING OF FLOW AND RUN ACROSS DIFFERENT AGES AND OTHER INFANT FACTORS. THESE EVIDENCE-BASED RATES WILL BE INCORPORATED INTO THE BOTTLE PROGRAMMING AND WILL PLAY BASED ON UNIQUE INFANT FACTORS THAT THE FEEDER ENTERS ON THE PREEMIE-PACER, WITH THE ABILITY TO ADJUST THE RATES IF NEEDED. THIS WORK WILL SET THE STAGE FOR CLINICAL TRIALS ON SAFETY AND EFFICACY. THE PREEMIE-PACER CAN HAVE A SIGNIFICANT IMPACT ON THE CARE THAT PRETERM INFANTS RECEIVE. IF SAFE AND EFFICIENT ORAL FEEDING CAN BE ACHIEVED EVEN A FEW DAYS EARLIER, SIGNIFICANT HEALTH CARE DOLLARS CAN BE SAVED, AND INFANTS CAN BE DISCHARGED TO THEIR HOMES EARLIER. IN ADDITION, PARENTS CAN POTENTIALLY HAVE MORE SUCCESS AND CONFIDENCE IN FEEDING THEIR HIGH-RISK PRETERM INFANTS.

PARENT TRAINING AND INFORMATION CENTER

PACER'S PROJECT LAUNCH

MODELS PROMOTING YOUNG CHILDREN'S USE OF ASSISTIVE TECHNOLOGY

SPECIAL EDUCATION-TRAINING AND INFORMATION FOR PARENTS OF CHILDREN WITH DISABILITIES - PARENT TRAINING AND INFORMATION CENTER

HLTH CARE INFORMATION & EDUCATION FOR FAMILIES OF CHILDREN W/SPECIAL HLTH CARE N

PACER'S FAMILY SUPPORT TRAINING PROJECT

DEMONSTRATION AND TRAINING PROGRAM/PARENT INFORMATION AND TRAINING

TECHNICAL ASSISTANCE

HLTH CARE INFORMATION & EDUCATION FOR FAMILIES OF CHILDREN W/SPECIAL HLTH CARE N

PNS: PACER'S FAMILIES ACCESSING COMMUNITIES TOGETHER PROJECT

DEMONSTRATION AND TRAINING PROGRAM/PARENT INFORMATION AND TRAINING

MINNESOTA PARENT TRAINING AND INFORMATION CENTER

USING IN-VIVO REAL-TIME BIOSENSOR TO EVALUATE PRODRUGS DESIGNED TO PROLONG THERAPEUTIC EFFECTS FOR SMOKING CESSATION. - ABSTRACT DEVELOPING DRUGS THAT TARGET THE CENTRAL NERVOUS SYSTEM (CNS) IS HAMPERED BY AN INABILITY TO PERFORM DIRECT IN VIVO PRECLINICAL MEASUREMENTS. HERE, WE PROPOSE TO IDENTIFY AN OPTIMAL SMOKING CESSATION DRUG CANDIDATE BY MONITORING HOW OUR NEWLY SYNTHESIZED PRODRUGS ALTER REAL-TIME BRAIN DOPAMINE RESPONSES TO NICOTINE. VARENICLINE (CHANTIX®) IS THE LEADING FDA-APPROVED ORAL MEDICATION FOR SMOKING CESSATION. HOWEVER, ONLY 22% OF PATIENTS MAINTAIN ABSTINENCE FOR 52 WEEKS FOLLOWING VARENICLINE TREATMENT1 AND 67% OF PATIENTS STOP TREATMENT PREMATURELY2, SUGGESTING THAT THERAPIES WITH BETTER PATIENT COMPLIANCE ARE NEEDED. TO ADDRESS THIS NEED, WE RECENTLY DEVELOPED EXTENDED-RELEASE PRODRUGS THAT ARE DESIGNED TO IMPROVE THE PHARMACOKINETIC PROPERTIES OF VARENICLINE. VARENICLINE REDUCES NICOTINE CRAVING AND USE BY DUAL ACTION: FIRST PROVIDING A TRANSIENT INCREASE IN DOPAMINE LEVELS AND SUBSEQUENTLY BY BLOCKING THE DOPAMINE RESPONSE TO NICOTINE3-5. THESE CHANGES AIM TO STABILIZE DOPAMINE SIGNALING IN THE BRAIN TO ACHIEVE TWO GOALS: (1) REDUCE THE SIDE EFFECTS OF TRANSIENTLY DOPAMINE INCREASES AND (2) PROLONG THE DURATION WITH WHICH THE DRUG REDUCES THE REWARD VALUE OF NICOTINE. IN THIS PHASE I GRANT, WE WILL USE AN IN VIVO DOPAMINE BIOSENSOR TO EVALUATE REAL-TIME DOPAMINE LEVELS IN THE STRIATUM (A REWARD CENTER IN THE BRAIN) FOLLOWING ADMINISTRATION OF OUR NOVEL PRODRUGS. WE WILL ESTABLISH AN IN VIVO RELATIONSHIP BETWEEN BRAIN EFFICACY (AS DEFINED BY DOPAMINE RELEASE) AND DRUG LEVELS IN CIRCULATION. THESE STUDIES WILL ALLOW US TO SCREEN FOR PRODRUGS THAT HAVE OPTIMAL EFFICACY FOR ALTERING BOTH THE LEVEL AND DURATION OF DOPAMINE RESPONSE, WHICH WE USE AS A BIOMARKER FOR PREDICTING EFFICACY FOR SMOKING CESSATION. THE PRIMARY HYPOTHESIS OF THIS PHASE I GRANT IS THAT A PRODRUG THAT STABILIZES THE INITIAL DOPAMINE RELEASE IN THE STRIATUM WHILE ALSO MORE EFFICIENTLY BLOCKING SUBSEQUENT DOPAMINE RESPONSES TO NICOTINE WILL BE MORE EFFECTIVE THAN VARENICLINE AT DECREASING IV SELF-ADMINISTRATION OF NICOTINE. WE WILL TEST THIS HYPOTHESIS BY: 1) ESTABLISHING PHARMACOKINETICS FOR EACH PRODRUG RELATIVE TO VARENICLINE; 2) MEASURING STRIATAL DOPAMINE LEVELS USING REAL-TIME IN VIVO BIOSENSORS TO DETERMINE HOW DIFFERENT EXPOSURE CURVES AFFECT DOPAMINE RESPONSE; AND 3) ASSESSING BEHAVIORAL CHANGES IN RESPONSE TO THE PRODRUGS USING A WELL-ESTABLISHED NICOTINE ADDICTION MODEL. OUR INITIAL PILOT DATA DEMONSTRATE THAT, IN COMPARISON TO VARENICLINE, OUR PRODRUGS FAVORABLY ALTER THE DOPAMINE RELEASE PROFILE IN THE STRIATUM. THUS, OUR PRODRUG APPROACH CHANGES THE PHYSIOLOGICAL FUNCTION OF THE REWARD SYSTEM AND MAY BE A BETTER DRUG FOR CLINICAL USE. IMPORTANTLY, THE CORE TECHNOLOGY USED IN THIS GRANT TO DEVELOP IMPROVED SMOKING CESSATION DRUGS CAN BE UTILIZED MORE BROADLY AS A GENERAL PHARMACODYNAMIC ASSAY FOR CNS DRUG DEVELOPMENT. THEREFORE, THIS RESEARCH WILL PROVIDE A PLATFORM FOR DRUG DISCOVERY USING IN VIVO REAL- TIME METHODOLOGIES. SPACERX HAS EXTENSIVE EXPERIENCE MAKING VARENICLINE ANALOGS AND PRODRUGS, AND REAL- TIME BIOSENSING AND MEASURING NEURAL ACTIVITY DYNAMICS IS A CORE TECHNOLOGY OF THE BETLEY LABORATORY, MAKING OUR TEAM IDEALLY SUITED TO TEST OUR HYPOTHESIS TO SUCCESSFULLY DEVELOP NOVEL SMOKING CESSATION DRUGS.

PACER'S MINNESOTA STATEWIDE FAMILY NETWORK - PACER CENTER'S MINNESOTA STATEWIDE FAMILY NETWORK (MSFN) PROJECT – ABSTRACT MSFN WILL HAVE A SIGNIFICANT IMPACT ON THE STATE’S MENTAL HEALTH SYSTEMS BY INCREASING FAMILIES’ CAPACITY TO NAVIGATE SYSTEMS AND PARTICIPATE IN MENTAL HEALTH POLICY, PLANNING, AND IMPLEMENTATION. PACER WILL DEVELOP PARENT AND YOUTH LEADERS, PROVIDE INDIVIDUAL ADVOCACY AND SUPPORT, INFORM POLICYMAKERS ABOUT THE SERVICE GAPS, AND EDUCATE THE PUBLIC ABOUT MENTAL HEALTH ISSUES EXPERIENCED BY FAMILIES. THE PRIMARY POPULATION TO BE SERVED BY THIS PROJECT IS FAMILIES AND CAREGIVERS OF CHILDREN, YOUTH, AND YOUNG ADULTS WITH SERIOUS EMOTIONAL DISTURBANCE (SED) ACROSS THE STATE OF MINNESOTA, AS WELL AS RELATED PROFESSIONALS WHO WORK WITH THEM. MSFN GOALS AND OBJECTIVES ARE: GOAL 1. TRANSFORM MN’S MENTAL HEALTH AND RELATED SYSTEMS BY INCREASING LEADERSHIP AND PARTICIPATION OF FAMILIES AND YOUTH IN BEHAVIORAL HEALTH POLICY DEVELOPMENT AND IMPLEMENTATION. OBJ. 1.1. SUPPORT 15-20 FAMILY AND YOUTH LEADERS ANNUALLY THROUGH TRAINING AND ONGOING SUPPORT ACTIVITIES. GOAL 2. IMPROVE ACCESS TO SERVICES FOR CHILDREN, YOUTH, AND YOUNG ADULTS WITH SERIOUS EMOTIONAL DISTURBANCE BY PROVIDING INFORMATION AND SUPPORT TO FAMILIES AND PROFESSIONALS. OBJ. 2.1. PROVIDE AT LEAST 1,500 INSTANCES OF INDIVIDUAL ASSISTANCE VIA PHONE, EMAIL, AND IN-PERSON MEETINGS WITH FAMILIES, CAREGIVERS, AND PROFESSIONALS. OBJ. 2.2. CONDUCT A MINIMUM OF 13 TRAININGS AND PRESENTATIONS IN MULTIPLE FORMATS FOR FAMILIES AND PROFESSIONALS. GOAL 3: SHARE INFORMATION ABOUT EXPERIENCES OF FAMILIES OF CHILDREN AND YOUTH WITH SERIOUS EMOTIONAL DISTURBANCE TO INCREASE AWARENESS OF POLICYMAKERS, STAKEHOLDERS, AND THE GENERAL PUBLIC. OBJ.3.1. PARTICIPATE IN A MINIMUM OF 12 MEETINGS OR COLLABORATIVE ACTIVITIES TO PROVIDE INPUT AND FEEDBACK ABOUT MENTAL HEALTH ISSUES FACED BY FAMILIES AND CAREGIVERS OF CHILDREN AND YOUTH WITH SED. OBJ. 3.2. DEVELOP PRINT AND ONLINE RESOURCES ON MENTAL HEALTH TOPICS AND DISTRIBUTE TO MORE THAN 200,000 FAMILIES, PROFESSIONALS, AND OTHERS ANNUALLY. GOAL 4. COLLECT DATA AND EVALUATE ACTIVITIES TO ENSURE MSFN PROJECT IS ACHIEVING MEASURABLE OBJECTIVES AND HAVING DESIRED IMPACT. OBJ. 4.1. COLLECT NECESSARY DATA TO REPORT ON REQUIRED PERFORMANCE MEASURES AND PROJECT-SPECIFIC OBJECTIVES. OBJ. 4.2. REVIEW EVALUATION DATA QUARTERLY TO ASSESS PROGRESS AND MAKE NECESSARY CHANGES TO PROJECT DELIVERY TO IMPROVE IMPACT. PACER WILL UTILIZE THE FOLLOWING STRATEGIES AND INTERVENTIONS TO ACHIEVE THE MSFN’S PROJECT OBJECTIVES: HOLD FAMILY LEADERSHIP SUMMIT; DEVELOP YOUTH BOARD’S LEADERSHIP AND ADVOCACY SKILLS; PROMOTE ONGOING POLICY ENGAGEMENT OPPORTUNITIES; PROVIDE INDIVIDUAL ASSISTANCE, SUPPORT, AND POLICY INFORMATION TO FAMILIES; CONDUCT WORKSHOPS FOR FAMILIES AND PROFESSIONALS; PROVIDE CULTURALLY COMPETENT TRAINING AND INFORMATION TO CULTURALLY AND LINGUISTICALLY DIVERSE FAMILIES; PARTICIPATE IN STAKEHOLDER MEETINGS WITH STATE AND LOCAL MENTAL HEALTH, EDUCATION, AND HEALTH AGENCIES; ADVOCATE FOR IMPROVED MENTAL HEALTH STATE POLICIES; DEVELOP NEW WRITTEN AND VIDEO RESOURCES FOR FAMILIES AND PROFESSIONALS; DISSEMINATE INFORMATION THROUGH ELECTRONIC AND PRINT NEWSLETTERS AND SOCIAL MEDIA; COLLECT DATA AND EVALUATE EFFECTIVENESS OF PROJECT ACTIVITIES. PACER’S MSFN WILL SERVE APPROXIMATELY 1,750 DUPLICATED FAMILY MEMBERS AND PROFESSIONALS ANNUALLY AND 5,250 TOTAL OVER THE LIFETIME OF THE PROJECT THROUGH INDIVIDUAL ASSISTANCE AND TRAINING. THOUSANDS MORE WILL BE REACHED THROUGH DISSEMINATION AND OUTREACH. PACER LOOKS FORWARD TO CONTINUING ITS STRONG HISTORY OF PARTNERING WITH POLICYMAKERS AND SUPPORTING FAMILIES TO IMPROVE THE STATE’S SERVICES FOR CHILDREN AND YOUTH WITH SED AND THEIR FAMILIES.

REVOLUTIONIZING NICOTINE VAPING AND ELECTRONIC NICOTINE DELIVERY SYSTEMS ADDICTION TREATMENT THROUGH INNOVATIVE E-VAPE ADMINISTRATION OF CYTISINE TO ENHANCE PATIENT ADHERENCE AND TREATMENT COMPLETION. - ABSTRACT NICOTINE ADDICTION IS A PERSISTENT PUBLIC HEALTH CHALLENGE, AND SMOKING REMAINS THE LEADING CAUSE OF PREVENTABLE DISEASE AND DEATH IN THE UNITED STATES. AS OF 2021, AN ESTIMATED 46 MILLION AMERICANS SMOKE TOBACCO PRODUCTS OR USE E-CIGARETTES. THIS BEHAVIOR IMPOSES A FINANCIAL BURDEN OF OVER $600 BILLION ANNUALLY, INCLUDING NEARLY $240 BILLION FOR DIRECT MEDICAL CARE AND ALMOST $180 BILLION IN LOST PRODUCTIVITY DUE TO ILLNESS AND PREMATURE DEATH. WHILE APPROXIMATELY 70% OF THOSE WITH NICOTINE DEPENDENCE EXPRESS A DESIRE TO QUIT, ONLY ONE IN TEN SUCCESSFULLY ACHIEVE NICOTINE ABSTINENCE FOR 12 MONTHS OR MORE THROUGH NICOTINE REPLACEMENT THERAPY (NRT) AND NON-NICOTINE MEDICATIONS FOR SMOKING CESSATION. THIS LOW SUCCESS RATE HIGHLIGHTS THE URGENT NEED FOR AN INNOVATIVE APPROACH THAT GOES BEYOND RELIEVING NICOTINE CRAVINGS. SMOKING AND VAPING ARE COMPLEX BEHAVIORS DEEPLY INGRAINED THROUGH LONG-TERM CONDITIONING. QUITTING INVOLVES NOT ONLY ENDING NICOTINE USE BUT ALSO NAVIGATING SOCIAL SETTINGS, MANAGING ISOLATION FROM SOCIAL NETWORKS, AND COPING WITH HABITUAL ORAL FIXATIONS. TO ADDRESS THIS UNMET NEED, WE ARE DEVELOPING A TREATMENT BASED ON THE SMOKING CESSATION DRUG CANDIDATE, CYTISINE, TO BE SELF-ADMINISTERED IN VAPE FORM USING AN E-CIGARETTE OR "VAPE PEN." WE PROPOSE THAT THIS APPROACH WOULD SERVE AS AN EFFECTIVE SECONDARY LINE OF THERAPY FOR INDIVIDUALS SEEKING E-CIGARETTE AND SMOKING CESSATION, PARTICULARLY THOSE WHO HAVE EXPERIENCED TWO OR MORE UNSUCCESSFUL ATTEMPTS WITH EXISTING NRT. IT WOULD ALLOW THEM TO ENGAGE IN MANY SMOKING-RELATED BEHAVIORS WHILE SIMULTANEOUSLY REDUCING THEIR NICOTINE DEPENDENCE. WHILE THE ORAL ADMINISTRATION OF CYTISINE FOR SMOKING CESSATION IS WELL-ESTABLISHED, OUR INNOVATION LIES IN EXPLORING THE FEASIBILITY OF DELIVERING CYTISINE IN VAPE FORM. THE PRIMARY HYPOTHESIS OF THIS PHASE I GRANT IS THAT DELIVERING CYTISINE THROUGH ELECTRONIC VAPE ADMINISTRATION (EVA) WILL SUFFICIENTLY STABILIZE DOPAMINE RELEASE IN THE BRAIN, SPECIFICALLY THE VENTRAL STRIATUM, THEREBY REDUCING NICOTINE SELF-ADMINISTRATION IN A MOUSE MODEL OF NICOTINE ADDICTION. TO TEST THIS HYPOTHESIS, WE WILL, 1) DETERMINE THE PHARMACOKINETICS OF CYTISINE BY QUANTIFYING PLASMA CYTISINE CONCENTRATIONS AFTER BOTH ORAL AND VAPE ADMINISTRATION IN A RODENT MODEL, 2) UTILIZE A BIOSENSOR PLATFORM, DLIGHT1.3B, TO MONITOR CORE DOPAMINE LEVELS IN VIVO DURING NICOTINE SELF-ADMINISTRATION, AND 3) EVALUATE THE POTENTIAL ABUSE LIABILITY OF EVA CYTISINE IN E-VAPE SELF-ADMINISTRATION (EVSA) AND ASSESS THE ABILITY OF EVA CYTISINE TO REDUCE NICOTINE REINFORCEMENT USING TRAINED AND NICOTINE-CONDITIONED MICE IN A NICOTINE EVSA PARADIGM. THIS PROPOSAL PROVIDES THE FOUNDATION FOR DEVELOPING AN E-CIGARETTE VAPING AND SMOKING CESSATION PRODUCT THAT OFFERS A SUPERIOR METHOD OF TREATMENT TAILORED FOR PATIENTS WHO HAVE NOT BEEN SUCCESSFUL WITH TRADITIONAL NRT AND ORAL ADMINISTRATION TREATMENTS. OUR TEAM IS UNIQUELY POSITIONED TO ACHIEVE THIS AIM. SPACERX HAS EXTENSIVE EXPERIENCE IN SMOKING CESSATION DRUGS AND PRODRUGS, AND THE HENDERSON LABORATORY SPECIALIZES IN THE NEUROPHARMACOLOGY OF NICOTINE ADDICTION.

PROJECT LAUNCH

PACER'S MINNESOTA STATEWIDE FAMILY NETWORK

SBIR PHASE I: MULTIPLE ACCESS LASER COMMUNICATION TERMINALS FOR OPTICAL ORBITAL HOTSPOTS -THE BROADER IMPACT/COMMERCIAL POTENTIAL OF THIS SMALL BUSINESS INNOVATION RESEARCH (SBIR) PHASE I PROJECT LIES IN THE DEVELOPMENT OF AN OPTICAL ORBITAL HOTSPOT NETWORK THAT WILL ENHANCE SATELLITE DATA COLLECTION AND UTILIZATION. THIS INNOVATION IS PROJECTED TO MAKE SMALL SATELLITES OPERATING MORE EFFICIENT AND ACCESSIBLE, THUS EMPOWERING BUSINESSES, AGENCIES, AND NEW ENTRANTS. THE EXPECTED RESULT IS AN INCREASE IN DATA GENERATION AND TRANSFER, IMPROVING CONNECTIVITY TO CLOUD-BASED SERVICES AND LOW EARTH ORBIT (LEO) SPACE-BASED PLATFORMS. BY DECREASING THE TECHNICAL AND COST BARRIERS TO LEO ACCESS, RAPID INNOVATION WILL BE ENABLED, LEVERAGING EXISTING AEROSPACE RESEARCH. THIS DEVELOPMENT IS ALIGNED WITH A GROWING MARKET, WITH THE SATELLITE LASER COMMUNICATION MARKET EXPECTED TO REACH $4.1B BY 2031. THE COMMERCIAL IMPLICATIONS ARE VAST, INCLUDING OPPORTUNITIES TO ADDRESS AN EVEN LARGER SATELLITE GROUND STATION MARKET, WITH THE POTENTIAL TO ENABLE TRANSFORMATIONAL OPPORTUNITIES ACROSS VARIOUS SECTORS. THIS SBIR PHASE I PROJECT PROPOSES TO DEVELOP AND REFINE THE TECHNOLOGY FOR AN OPTICAL ORBITAL HOTSPOT NETWORK INTEGRATION AND IMPLEMENT ADVANCED BEAM STEERING TECHNOLOGIES. THE PRIMARY CHALLENGES LIE IN THE CREATION OF MULTI-ACCESS LASERCOM TERMINALS (MALT) AND THE DEVELOPMENT OF ORBITAL OPTICAL HOTSPOT TECHNOLOGY. THE RESEARCH WILL MATURE THE OPTICAL DESIGNS OF THE MALT AND COMPACT USER LASERCOM TERMINAL SYSTEMS (MICRO-LCT). RESEARCH AND OBJECTIVES TO BE ADDRESSED RANGE FROM OPERATIONS DEVELOPMENT TO PRELIMINARY HARDWARE DESIGN. THE ANTICIPATED TECHNICAL RESULTS WILL INCLUDE THE ESTABLISHMENT OF ORBITAL MODELS, MULTIBEAM STEERING TECHNOLOGY DEVELOPMENT, INTERFACE AND REQUIREMENTS DEFINITION, AND DESIGN FOR THE MALT AND MICRO-LCT SYSTEMS. THESE EFFORTS WILL COLLECTIVELY SOLVE THE 'LAST MILE PROBLEM' FOR SMALL SIZE, WEIGHT, POWER, AND COST SATELLITES, ENHANCING CAPABILITIES AND LOWERING HIGH DATA RATE COMMUNICATION BARRIERS IN THE EARTH OBSERVING SYSTEMS MARKET. THIS AWARD REFLECTS NSF'S STATUTORY MISSION AND HAS BEEN DEEMED WORTHY OF SUPPORT THROUGH EVALUATION USING THE FOUNDATION'S INTELLECTUAL MERIT AND BROADER IMPACTS REVIEW CRITERIA.- SUBAWARDS ARE NOT PLANNED FOR THIS AWARD.

INTEGRATED COMMUNITY SYSTEMS FOR CSHCN

PACERS MINNESOTA STATEWIDE FAMILY NETWORK

THE PREEMIE-PACER: AN INNOVATIVE BOTTLE TO PROMOTE SAFE AND EFFICIENT ORAL FEEDING IN PRETERM INFANTS

PACER'S MINNESOTA STATEWIDE FAMILY NETWORK

YOUTH LEADERSHIP

ENTREPRENEURSHIP